source
- Crystalys Therapeutics raises $130M Series B to advance gout drug dotinurad toward global launchCrystalys Therapeutics announced a $130 million Series B financing to move its gout drug dotinurad through late-stage trials and prepare for commercial launch. The round was led by Frazier Life Sc…
- Vertex's $10 billion Crinetics buyout draws investor doubts over premium priceVertex was the lone bidder in a planned $10 billion acquisition of Crinetics Pharmaceuticals, a California company that focuses on endocrine medicines. Crinetics currently markets a therapy for a…